269 related articles for article (PubMed ID: 15729304)
1. Vioxx may go back on sale after scraping past FDA panel.
Wadman M
Nature; 2005 Feb; 433(7028):790. PubMed ID: 15729304
[No Abstract] [Full Text] [Related]
2. Make or break time in Vioxx drama.
Nature; 2006 Mar; 440(7082):277. PubMed ID: 16541045
[No Abstract] [Full Text] [Related]
3. Drug firms back-pedal on direct advertising.
Nature; 2005 Aug; 436(7053):910-1. PubMed ID: 16107811
[No Abstract] [Full Text] [Related]
4. Drug safety on trial.
Nature; 2005 Mar; 434(7033):545. PubMed ID: 15800579
[No Abstract] [Full Text] [Related]
5. [Vision impairment by COX-2 inhibitor and the sequelae of voluntary Vioxx recall].
Meyer CH
Klin Monbl Augenheilkd; 2005 Jan; 222(1):62-3. PubMed ID: 15678404
[No Abstract] [Full Text] [Related]
6. Drug safety. FDA panel urges caution on many anti-inflammatory drugs.
Couzin J
Science; 2005 Feb; 307(5713):1183-5. PubMed ID: 15731414
[No Abstract] [Full Text] [Related]
7. Regulatory paternalism in the market for drugs: lessons from Vioxx and Celebrex.
Epstein RA
Yale J Health Policy Law Ethics; 2005; 5(2):741-70. PubMed ID: 16052898
[No Abstract] [Full Text] [Related]
8. Will Merck survive Vioxx?
Simons J; Stipp D
Fortune; 2004 Nov; 150(9):90-2, 94, 96-7 passim. PubMed ID: 15543824
[No Abstract] [Full Text] [Related]
9. Painkiller in the dock.
Nature; 2005 Jul; 436(7050):459. PubMed ID: 16049447
[No Abstract] [Full Text] [Related]
10. [Cyclooxygenase inhibitors: a never ending story?].
Macrì R; Manfredi C
G Ital Cardiol (Rome); 2006 Jul; 7(7):505-7. PubMed ID: 16977790
[No Abstract] [Full Text] [Related]
11. What ails the FDA?
Okie S
N Engl J Med; 2005 Mar; 352(11):1063-6. PubMed ID: 15784660
[No Abstract] [Full Text] [Related]
12. The COX-2 inhibitors--an update.
Furberg CD
Am Heart J; 2006 Aug; 152(2):197-9. PubMed ID: 16875896
[No Abstract] [Full Text] [Related]
13. Anticipating a Vioxx defense strategy: will corporate honesty be enough?
Willis KD
Tort Trial Insur Pract Law J; 2006; 41(4):1163-78. PubMed ID: 17091567
[No Abstract] [Full Text] [Related]
14. How Vioxx is changing US drug regulation.
Zwillich T
Lancet; 2005 Nov; 366(9499):1763-4. PubMed ID: 16302300
[No Abstract] [Full Text] [Related]
15. Drug safety special: the safety catch.
Wadman M
Nature; 2005 Mar; 434(7033):554-6. PubMed ID: 15800591
[No Abstract] [Full Text] [Related]
16. A bitter pill for one Merck critic.
McLean B
Fortune; 2004 Dec; 150(12):58. PubMed ID: 15617422
[No Abstract] [Full Text] [Related]
17. Journal grows suspicious of Vioxx data.
Wadman M
Nature; 2005 Dec; 438(7070):899. PubMed ID: 16355178
[No Abstract] [Full Text] [Related]
18. Rofecoxib, Merck, and the FDA.
Villalba L; Witter J
N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625745
[No Abstract] [Full Text] [Related]
19. Avoiding another Vioxx.
Beardsley S
Sci Am; 2005 Feb; 292(2):16, 18. PubMed ID: 15715381
[No Abstract] [Full Text] [Related]
20. The pain game.
Wadman M
Nature; 2007 Jul; 448(7152):400-1. PubMed ID: 17653159
[No Abstract] [Full Text] [Related]
[Next] [New Search]
